Bibliografía

1.     Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA,

2.     Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002 Mar 15;34(6):730-51

3.     Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.

4.     Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis. 2002 Aug;15(4):377-82.

5.     De Pauw B. Infections in patients with hematologic malignancies. In: Rolston KVI, Rubenstein EB, eds. Textbook of Febrile Neutropenia. 1st ed. Great Britain: Martin Dunitz Ltd. 2001: 111-124.

6.     Rolston KVI. Expanding the options for risk-bases therapy in febrile neutropenia. Diagn Microbiol Infect Dis 1998;31:411-416.

7.     Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. Clinical Infectious Diseases 1993;17(Suppl 2):S378-84.

8.     Rolston KVI. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clinical Infectious Diseases 1999;29:515-21.

9.     Yadegarynia D, Rolston KVI, Tarrand J, Raad II. Current spectrum of bacterial infection in patients with hematological malignancies and solid tumors. Abstracts of the 40th Annual Meeting of

10.  Infectious Diseases Society of America (IDSA), Abstract 139, Chicago, Illinois, USA, 2002.

11.  Ramphal R. Is Monotherapy for Febrile Neutropenia Still a Viable Alternative?. Clinical Infectious Diseases 1999;29:508-14.

12.  Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The multinational association for supportive care in cáncer risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. Clin Oncol. 2000 Aug;18(16):3038-51.

13.  Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer. 2003 Jul 7;89(1):43-49

14.  De Pauw BE. Treatment of documented and suspected neutropenia-associated invasive fungal infections. J Chemother. 2001 Nov;13 Spec No 1(1):181-92.

15.  Graybill J. The future of antifungal therapy. Clinical Infectious Diseases 1996; 22(Suppl.2): 166-78.

16.  Rolston KV. Fungal infections in immunosuppressed cancer patients. Med Microbiol Lett 1996; 5:315-318.

17.  Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KV . Infections in the neutropenic patient--new views of an old problem. Hematology (Am Soc Hematol Educ Program). 2001;113 -39.

18.  Meyer RD, Singer C. Overview of patients with neutropenia: Old and New Treatment Modalities. Clinical Infectious Diseases 1993;17(Suppl 2):S390 -1.

19.  Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winn RJ, Wozniak AJ, Somerfield MR American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000 Oct 15;18(20):3558-85.

20.  http://www.cancer. org/ download s/CRI/NCCN_ Fever _2002.pdf

21.  http://www. ccs publishing .com/ journals2a/ Neutropenic _Fever .htm